State Street SPDR S&P Pharmaceuticals ETF
XPH
66 hedge funds and large institutions have $109M invested in State Street SPDR S&P Pharmaceuticals ETF in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 22 reducing their positions, and 23 closing their positions.
1,650% more call options, than puts
Call options by funds: $3.57M | Put options by funds: $204K
12% less funds holding
Funds holding: 75 → 66 (-9)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
36.52% less ownership
Funds ownership: 96.97% → 60.45% (-37%)
45% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 22
51% less capital invested
Capital invested by funds: $224M → $109M (-$115M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$25M |
| 2 |
Morgan Stanley
New York
|
+$20M |
| 3 |
FMP
Financial Management Professionals
Austin,
Texas
|
+$3.22M |
| 4 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
+$2.91M |
| 5 |
SCA
Snowden Capital Advisors
New York
|
+$838K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$56.5M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$38.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$23M |
| 4 |
Goldman Sachs
New York
|
-$10.5M |
| 5 |
Barclays
London,
United Kingdom
|
-$2.02M |
XPH Hedge Fund Activity: Q1 2020 in Review
66 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2020, worth a combined $109M — down 51% from $224M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of XPH and 17 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 12 added.
The largest buyer was JP Morgan Chase, adding an estimated $25M. The largest seller was Credit Suisse, exiting entirely with an estimated $56.5M sold.
- 66 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2020, down from 75 in Q4 2019.
- Funds reported $109M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2020, down 51% quarter-over-quarter.
- 17 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2020 and 23 closed out, a net change of -6 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2020 was JP Morgan Chase, an estimated $25M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2020 was Credit Suisse, an estimated $56.5M sold.
Based on aggregated 13F filings for Q1 2020.